Supervisor View Full Details

• cell and developmental biology/regenerative medicine
• Other - please suggest keyword(s):

• Medicine
• Emergency Medicine

• Cardiology
• Clinical Trials

The HRB funded Irish Critical Care-Clinical Research Core (ICC-CRC) is a methodology hub which represents a group of highly motivated clinicians, nurses and scientists working collaboratively to improve outcomes in critically ill patients in Ireland. Our network offers ICU patients the highest quality care and gives them access to the latest innovations in intensive care. Since it was established in 2015 the ICC-CRC has lead the PHARLAP, TRANSFUSE and the PEPTIC trials in Ireland. PHARLAP- will establish whether the way we ?set? the breathing machine helps reduce further lung damage in patients with a severe lung disease (Acute Respiratory Distress Syndrome ARDS). ? TRANSFUSE- Does giving ?fresher? blood versus ?older blood? in transfusions make a difference to patients who are admitted to ICU. This study will result in a worldwide practice change if it finds freshest available blood use is best for ICU patients. ?PEPTIC Carrying out test studies to determine which of the common treatments used to help reduce bleeding from the stomach is best. In addition to the HRB funded studies the ICC-CRC is the lead site for STARRT-AKI, STOP-AKI and the ADSCAP trials.

ICC-CTC Publications (see www.iccctg.org)
Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial. Nichol A, French C, Little L, Haddad S, Presneill J, Arabi Y, Bailey M, Cooper DJ, Duranteau J, Huet O, Mak A, McArthur C, Pettil? V, Skrifvars M, Vallance S, Varma D, Wills J, Bellomo R; EPO-TBI Investigators and the ANZICS Clinical Trials Group. Lancet. 2015 Oct 6

Acute Kidney Injury (AKI) occurs in over half of those admitted to the Intensive Care Unit (ICU). The sequelae commonly includes acute renal failure, emergency dialysis and death. We will develop and establish a bio-marker evaluation, discovery and validation hub in Ireland. We have obtained agreement to collaborate with critical care trialists from Europe, Canada, Australia and New Zealand. They are willing to share data and samples in critically ill patients who have been randomised into completed (and ongoing) randomised controlled trials with long term follow up.
This project aims to identify biomarkers which can be used to predict the development of AKI, the recovery of AKI and accordingly develop novel diagnostic tools to guide interventions. This project involves key collaborations between academia and industry in Ireland and internationally. The UCD Clinical Research Center and bio-banking facility along with established industry collaborations will work with the Irish Critical Care Clinical Trials Core to establish a biomarker development hub in Ireland.
This will be a globally unique resource of biological samples (blood, urine and cerebrospinal fluid) linked with detained phenotyed data. We will investigate the effectiveness of the currently known biomarkers to accurately diagnose early Acute Kidney Injury and Brain Injury and to predict recovery (or not) across this large biological linked data set. Our collaborators, will conduct genomic sequencing, metabolomics and proteomic analysis in tandem with a systems biology approach to discover new biomarkers. We will then use our bio bank to validate the effectiveness of our new biomarkers. This resource is unexampled and has brought together a world class team of clinicians, trialists, basic scientists and industry. This would be of great benefit to patients, the doctors caring for them and researchers designing trials for new therapies whether from academia or industry.